

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

POSITIVE PROFIT ALERT

This announcement is made by China Shineway Pharmaceutical Group Limited (the “**Company**”), and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform its shareholders (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the Group’s unaudited consolidated management accounts, the Group’s profit attributable to the owners of the Company for the six months ended 30 June 2023 (the “**Period**”) is expected to increase by approximately 45% to 50% as compared with that for the corresponding period of last year (the corresponding period of 2022: RMB331,123,000).

The expected increase in the profit attributable to the owners of the Company for the Period is mainly attributable to (i) the increase in overall sales revenue of the Group of approximately 32% and (ii) the increase in gross profit and net profit margins as compared with that for the corresponding period of last year. During the Period, sales revenue of all dosage forms increased, and among them sales revenue of injection products and TCM formula granules products increased by approximately 37% and 34% respectively.

The information contained in this announcement is only based on the Board’s preliminary assessment with reference to the Group’s unaudited consolidated management accounts for the Period, which as at the date of this announcement are yet to be audited or reviewed by the Company’s auditors and may therefore be subject to change. The Group’s interim results for the Period are expected to be announced in due course in accordance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 3 August 2023

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Liu Tiejun; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Mr. Liu Shun Fai, Mr. Yew Yat On and Ms. Wang Guihua.